



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

NIMODIPINE SOLUTION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
NIMODIPINE	NYMALIZE		34794 43848 47984 47985 48405	GPI-14 (34000022002050) (34000022002054)	

GUIDELINES FOR USE

1. Does the patient have a history of subarachnoid hemorrhage (SAH) from a ruptured intracranial berry aneurysm within the past 21 days and meet **ALL** of the following criteria?
 - The patient is 18 years of age or older
 - The patient is unable to swallow nimodipine capsules

If yes, **approve once for the requested strength by GPID or GPI-14 up to a maximum 21 day supply with the following quantity limits:**

- Nymalize 30mg/10mL: #120mL per day.
- Nymalize 60mg/20mL: #120mL per day.
- Nymalize 30mg/5mL: #60mL per day.
- Nymalize 60mg/10mL: #60mL per day.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **NIMODIPINE SOLUTION (Nymalize)** requires the following rule(s) be met for approval:

- A. You have a history of subarachnoid hemorrhage (SAH: bleeding in the space surrounding your brain) from a ruptured intracranial berry aneurysm (an area of an artery wall in your brain ballooned and burst) within the past 21 days
- B. You are 18 years of age or older
- C. You are unable to swallow nimodipine oral capsules

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

NIMODIPINE SOLUTION

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nymalize.

REFERENCES

- Nymalize [Prescribing Information]. Atlanta, GA: Arbor Pharmaceuticals, Inc: April 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/26/21

Created: 08/13

Client Approval: 07/21

P&T Approval: 07/20